Richard Forshee
Overview
Explore the profile of Richard Forshee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
919
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deady M, Duncan R, Sonesen M, Estiandan R, Stimpert K, Cho S, et al.
J Med Internet Res
. 2024 Nov;
26:e54597.
PMID: 39586081
Background: Adverse events (AEs) associated with vaccination have traditionally been evaluated by epidemiological studies. More recently, they have gained attention due to the emergency use authorization of several COVID-19 vaccines....
2.
Gee J, Shimabukuro T, Su J, Shay D, Ryan M, Basavaraju S, et al.
Vaccine
. 2024 Apr;
42 Suppl 3:125748.
PMID: 38631952
The U.S. COVID-19 vaccination program, which commenced in December 2020, has been instrumental in preventing morbidity and mortality from COVID-19 disease. Safety monitoring has been an essential component of the...
3.
Rahman M, Dal Pan G, Stein P, Levenson M, Kraus S, Chakravarty A, et al.
Pharmacoepidemiol Drug Saf
. 2023 Oct;
33(1):e5715.
PMID: 37855046
No abstract available.
4.
Zhou Z, Cortese M, Fang J, Wood R, Hummell D, Risma K, et al.
Vaccine
. 2023 May;
41(28):4183-4189.
PMID: 37244808
Background: The mechanism for anaphylaxis following mRNA COVID-19 vaccination has been widely debated; understanding this serious adverse event is important for future vaccines of similar design. A mechanism proposed is...
5.
Hu M, Wong H, Feng Y, Lloyd P, Smith E, Amend K, et al.
JAMA Pediatr
. 2023 May;
177(7):710-717.
PMID: 37213095
Importance: Active monitoring of health outcomes after COVID-19 vaccination offers early detection of rare outcomes that may not be identified in prelicensure trials. Objective: To conduct near-real-time monitoring of health...
6.
Moll K, Lufkin B, Fingar K, Zhou C, Tworkoski E, Shi C, et al.
Vaccine
. 2022 Nov;
41(2):333-353.
PMID: 36404170
Background: The U.S. Food and Drug Administration (FDA) Biologics Effectiveness and Safety (BEST) Initiative conducts active surveillance of adverse events of special interest (AESI) after COVID-19 vaccination. Historical incidence rates...
7.
Near real-time surveillance of safety outcomes in US COVID-19 vaccine recipients aged 12 to 64 years
Lloyd P, Hu M, Wong H, Shoaibi A, Zhou C, Lo A, et al.
Vaccine
. 2022 Oct;
40(45):6481-6488.
PMID: 36195472
Background: Active monitoring of safety outcomes following COVID-19 vaccination is critical to understand vaccine safety and can provide early detection of rare outcomes not identified in pre-licensure trials. We present...
8.
Wong H, Hu M, Zhou C, Lloyd P, Amend K, Beachler D, et al.
Lancet
. 2022 Jun;
399(10342):2191-2199.
PMID: 35691322
Background: Several passive surveillance systems reported increased risks of myocarditis or pericarditis, or both, after COVID-19 mRNA vaccination, especially in young men. We used active surveillance from large health-care databases...
9.
Belov A, Huang Y, Villa C, Whitaker B, Forshee R, Anderson S, et al.
Am J Hematol
. 2022 Mar;
97(6):770-779.
PMID: 35303377
The efficacy of COVID-19 convalescent plasma (CCP) as a treatment for hospitalized patients with COVID-19 remains somewhat controversial; however, many studies have not evaluated CCP documented to have high neutralizing...
10.
Park H, Tarpey T, Liu M, Goldfeld K, Wu Y, Wu D, et al.
JAMA Netw Open
. 2022 Jan;
5(1):e2147375.
PMID: 35076698
Importance: Identifying which patients with COVID-19 are likely to benefit from COVID-19 convalescent plasma (CCP) treatment may have a large public health impact. Objective: To develop an index for predicting...